Maggie Tibbitt


Pembrolizumab/Chemo With or Without Bevacizumab Has Potential as New SOC in Metastatic Cervical Cancer

May 21st 2022

Nicoletta Colombo, MD, PhD, discusses the practice-changing data to emerge from KEYNOTE-826 and the next steps for the pembrolizumab plus chemotherapy with or without bevacizumab regimen in patients with cervical cancer.

Sotigalimab Plus Nivolumab Shows Encouraging Activity in Anti–PD-1 Refractory Melanoma

May 13th 2022

The combination of sotigalimab and nivolumab elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial.

Teclistamab/Daratumumab Combo Delivers Promising ORR in Heavily Pretreated Relapsed/Refractory Myeloma

May 10th 2022

Paula Rodriguez-Otero, MD, PhD, discusses the rationale, design, and findings of the phase 1b TRIMM-2 trial assessing subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma.

Cheng Explores the Evolution of Immunotherapy in the Cancer Field

March 12th 2022

Jonathan D. Cheng, MD, discusses the various categories of immuno-oncology, including checkpoint inhibitors, immunotherapy combinations, and TKIs, that are moving the modality forward.

Histology-Specific Trials and Drug Development Strategy Pave the Path to Progress in Soft Tissue Sarcoma

March 1st 2022

William D. Tap, MD, discusses the key challenges faced in the treatment of patients with soft tissue sarcoma and efforts being made to overcome them.

Talquetamab/Daratumumab Shows Promise in Heavily Pretreated Myeloma, Warranting Further Investigation

March 1st 2022

Ajai Chari, MD, discusses the safety and efficacy of talquetamab plus daratumumab in heavily pretreated patients with multiple myeloma, initial data from phase 1b TRIMM-2 trial, and the potential to move the combination into earlier lines of therapy.

Modakafusp Alfa Elicits Single-Agent Activity, Represents a Novel Option in Relapsed/Refractory Myeloma

February 12th 2022

Dan Vogl, MD, MSCE, discusses the unique mechanism of action of modakafusp alfa and the updated results from an expansion cohort in patients with relapsed/refractory multiple myeloma.

Upifitamab Rilsodotin Has Potential to Address Unmet Need in Recurrent Ovarian Cancer

January 31st 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the unmet needs for patients with ovarian cancer and the clinical trials that seeking to address those needs, including the ADC upifitamab rilsodotin.

Subcutaneous Epcoritamab Demonstrates Early Activity, Favorable Tolerability in CLL

January 16th 2022

Subcutaneous epcoritamab demonstrated early activity and favorable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia and high-risk features.

Immunotherapy Outcomes in HPV-Associated Head and Neck Cancer Fuel Investigative Efforts

January 14th 2022

Robert L. Ferris, MD, PhD, discusses the current standard of care for patients with head and neck cancer, the role of HPV in treatment decisions, and the need to personalize therapy for patients.

MB-106 Elicits Durable Responses and Demonstrates Tolerable Safety Profile in DLBCL, MCL, Follicular Lymphoma

January 13th 2022

Mazyar Shadman, MD, MPH, discusses the utility of MB-106 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia.

Adagrasib With or Without Cetuximab Produces Encouraging Clinical Activity in KRAS G12C–Mutant CRC

January 13th 2022

Jared Weiss, MD, sheds light on the exploration of adagrasib as a monotherapy and in combination with cetuximab in patients with KRAS G12C–mutated metastatic colorectal cancer, key findings from the KRYSTAL-1 study, and next steps for research.

Trastuzumab Deruxtecan Maintains PFS Benefit Across Subgroups in HER2+ Metastatic Breast Cancer

January 12th 2022

Sara Hurvitz, MD, discusses the findings from the subgroup analysis of the DESTINY-Breast03 trial, and future research directions for trastuzumab deruxtecan.

Polatuzumab Vedotin Plus R-CHP Emerges as Potential New Standard for Newly Diagnosed DLBCL

January 11th 2022

John M. Burke, MD, highlights the benefits derived with polatuzumab vedotin plus R-CHP and projects the next steps for the regimen.

Pembrolizumab Plus Enzalutamide Continues to Produce Antitumor Activity in Abiraterone Acetate-Pretreated mCRPC

January 11th 2022

The combination of pembrolizumab and enzalutamide continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who were previously treated with abiraterone acetate, according to data from cohort C of the phase 1b/2 KEYNOTE-365 trial.

Olaparib/Temozolomide Shows Encouraging Efficacy, Manageable Safety in Uterine Leiomyosarcoma

January 5th 2022

In patients with advanced uterine leiomyosarcoma whose tumors harbor a BRCA-like phenotype, the combination of olaparib with temozolomide could represent a new standard of care.

Allison Shares His Path to Groundbreaking Achievements in Immuno-Oncology

December 23rd 2021

James P. Allison, PhD, permanently etched his legacy into immuno-oncology with the development of ipilimumab, work that helped him win a Giants of Cancer Care® award for Scientific Advances in 2014.

Lipson Sheds Light on the Evolving Role of ctDNA in the Realm of Melanoma

December 23rd 2021

Evan J. Lipson, MD, discusses the role of ctDNA in the neoadjuvant, adjuvant, and metastatic settings in the realm of melanoma, remaining questions with this marker, and future directions to optimize its use in this disease.

Emerging Data With KO-539 and Other Menin Inhibitors Generate Excitement in AML

December 22nd 2021

Naval Daver, MD, discusses he encouraging early data that has been reported with KO-539 and other menin inhibitors in acute myeloid leukemia, data presented with novel KO-539 combinations in this disease, and next steps for research.

Surgical Resectability Remains Crucial in Determining Treatment Strategy in Liver-Only Metastatic CRC

December 20th 2021

Early identification of patients with liver-only metastatic colorectal cancer who are eligible for resection is crucial to determining their course of treatment and what role modalities like chemotherapy will play in their treatment strategy.